Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

Tanya C. Watt; Todd Cooper

doi:10.1002/pbc.23394

Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

Tanya C. Watt, Todd Cooper

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551-565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756-757.

Original language	English (US)
Pages (from-to)	756-757
Number of pages	2
Journal	Pediatric Blood and Cancer
Volume	59
Issue number	4
DOIs	https://doi.org/10.1002/pbc.23394
State	Published - Oct 2012

Keywords

AML
Pediatrics
Relapse
Sorafenib

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.23394

Cite this

@article{66403f9d831e4a0f8d2abe150ed6d262,

title = "Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia",

abstract = "The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551-565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756-757.",

keywords = "AML, Pediatrics, Relapse, Sorafenib",

author = "Watt, {Tanya C.} and Todd Cooper",

year = "2012",

month = oct,

doi = "10.1002/pbc.23394",

language = "English (US)",

volume = "59",

pages = "756--757",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

AU - Watt, Tanya C.

AU - Cooper, Todd

PY - 2012/10

Y1 - 2012/10

N2 - The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551-565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756-757.

AB - The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al. J Clin Oncol 2011; 29: 551-565]. However, the cure rate for AML lags behind that of acute lymphoblastic leukemia. Advances in AML leukemogenesis are leading to refined risk stratification. FMS like tyrosine kinase 3 (FLT3) mutations are independently associated with a poor prognosis. Newer kinase inhibitors, including sorafenib, have shown promise in adult studies. We report three pediatric patients with relapsed AML who achieved a sustained remission with sorafenib. Further trials are necessary to understand the role of sorafenib in pediatric AML. Pediatr Blood Cancer 2012;59:756-757.

KW - AML

KW - Pediatrics

KW - Relapse

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84864928986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864928986&partnerID=8YFLogxK

U2 - 10.1002/pbc.23394

DO - 10.1002/pbc.23394

M3 - Article

C2 - 22052552

AN - SCOPUS:84864928986

SN - 1545-5009

VL - 59

SP - 756

EP - 757

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

ER -

Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this